Japan to start OTC sales of emergency contraceptive in February

Daiichi Sankyo announced it will begin over-the-counter sales of the emergency contraceptive Norlevo on February 2, marking the first time such a pill is available without a prescription in Japan. The pill must be taken in the presence of a trained pharmacist for safety reasons.

Daiichi Sankyo announced on December 18 that it will launch over-the-counter sales of the emergency contraceptive pill Norlevo starting February 2 next year. Produced by Aska Pharmaceutical, the drug received approval from the health ministry in October for OTC availability, making it the first of its kind in Japan without requiring a prescription.

There are no age restrictions on purchasing Norlevo, allowing anyone to buy it. However, for safety, it must be taken under the supervision of a trained pharmacist. The pill is effective in preventing pregnancy in about 80% of cases when taken within 72 hours of intercourse. Its suggested retail price is ¥7,480 per pill.

This move aims to improve access to contraception, offering a new option for women's health management in the country. Key terms include pharmaceuticals, health, pregnancy, and birth control.

Articoli correlati

Illustration depicting a woman self-screening for medication abortion eligibility using prototype OTC packaging from a JAMA study.
Immagine generata dall'IA

Study finds many patients can self-screen for medication abortion eligibility using prototype labeling

Riportato dall'IA Immagine generata dall'IA Verificato

A study published April 6, 2026, in JAMA Internal Medicine found that people seeking medication abortion often reached the same eligibility conclusions as clinicians when using prototype “over-the-counter-style” packaging and a drug facts label. Researchers and outside experts said the results add to evidence that self-screening could work, though any move to over-the-counter sales would face major regulatory and political hurdles.

A new national survey and a string of coercion cases are intensifying calls from Republican lawmakers, state attorneys general, and advocacy groups for the FDA to restore tighter safeguards on abortion medications—pressure that comes even as federal health officials say they are reviewing mifepristone’s safety and the FDA has cleared a second generic version.

Riportato dall'IA

L'Agenzia nazionale di vigilanza sanitaria del Brasile (Anvisa) ha approvato il lenacapavir, commercializzato come Sunlenca, per l'uso come profilassi pre-esposizione (PrEP) contro l'HIV-1. Il farmaco, somministrato tramite iniezione sottocutanea ogni sei mesi, ha dimostrato un'efficacia fino al 100% in trial clinici con popolazioni vulnerabili. L'approvazione apre la strada a passi regolatori che potrebbero portare alla sua disponibilità nel Sistema Unico di Salute (SUS).

Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.

Riportato dall'IA

The National Economic Prosecutor's Office (FNE) actions to promote competition in the celecoxib anti-inflammatory market led to significant price drops and substantial savings for consumers and the state. Between 2017 and 2024, the drug's price fell 56% in pharmacies and 97% in health services, enabling 11 additional laboratories to enter the market.

Japan is considering revising its anti-prostitution law to include penalties for buyers of sex, aiming to close a loophole that currently only punishes sellers. Justice Minister Hiroshi Hiraguchi announced plans to form an expert panel for discussions this fiscal year. The move addresses growing concerns over street solicitation as a social issue.

Riportato dall'IA

The U.S. Department of Justice filed a motion on Friday to halt or dismiss a lawsuit by Missouri and other Republican-led states challenging the FDA's policy allowing mifepristone to be shipped through the mail. The filing argues that proceeding with the case would interfere with an ongoing FDA safety review of the drug initiated by the Trump administration. Pro-life advocates have criticized the move, urging stricter regulations on medication abortion.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta